Type 2 diabetes is often viewed as a disorder of glucose metabolism. But many factors come into play in this condition, with obesity a prime risk factor and cardiovascular disease a major result. In Bedside to Bench, Babak Razani and Clay Semenkovich examine the linkages between diabetes and cardiovascular disease. They call for new research approaches in the wake of clinical trials showing that lowering glucose levels does not decrease cardiovascular events in people with type 2 diabetes. In Bench to Bedside, Steven Shoelson and Allison Goldfine examine how type 2 diabetes and other disorders can stem from obesity—and its effect on inflammation. These authors take a look at two recent studies showing how obesity perturbs inflammatory gene networks.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gerstein, H.C. et al. N. Engl. J. Med. 358, 2545–2559 (2008).
Patel, A. et al. N. Engl. J. Med. 358, 2560–2572 (2008).
Duckworth, W. et al. N. Engl. J. Med. 360, 129–139 (2009).
University Group Diabetes Program. Diabetes 31, Suppl. 5, 1–81 (1982).
UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 837–853 (1998).
The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329, 977–986 (1993).
Nathan, D.M. et al. N. Engl. J. Med. 353, 2643–2653 (2005).
Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R. & Neil, H.A. N. Engl. J. Med. 359, 1577–1589 (2008).
Doria, A. et al. J. Am. Med. Assoc. 300, 2389–2397 (2008).
Schneider, J.G. et al. Cell Metab. 4, 377–389 (2006).
Bensaad, K. et al. Cell 126, 107–120 (2006).
Budanov, A.V. & Karin, M. Cell 134, 451–460 (2008).
Levine, B. & Deretic, V. Nat. Rev. Immunol. 7, 767–777 (2007).
Matsui, Y. et al. Circ. Res. 100, 914–922 (2007).
Jung, H.S. et al. Cell Metab. 8, 318–324 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
B.R. is supported by the Pfizer Junior Fellows Program at Washington University. C.F.S. has received speaker’s fees from Merck.
Rights and permissions
About this article
Cite this article
Razani, B., Semenkovich, C. Getting away from glucose: stop sugarcoating diabetes. Nat Med 15, 372–373 (2009). https://doi.org/10.1038/nm0409-372
Issue Date:
DOI: https://doi.org/10.1038/nm0409-372
